Skip to main content

Table 2 Raynaud's phenomenon and autoantibodies in scleroderma patients

From: Atypical clinical presentation of a subset of patients with anti-RNA polymerase III - non-scleroderma cases associated with dominant RNA polymerase I reactivity and nucleolar staining

 

RNAP III

(n= 18)

Topo I

(n= 24)

ACA

(n= 15)

U3RNP

(n= 9)

Th/To

(n= 8)

Prevalence of RP

94% (16/17)

96% (23/24)

100% (15/15)

100% (9/9)

87% (7/8)

Absence of RP at first visit

(in RP positive cases)

18% (3/16)1, 2

0% (0/23)2

0% (0/15)

0% (0/9)

0% (0/7)

Scleroderma prior to RP

31% (5/16)3, 4, 5

4% (1/23)3

0% (0/15)4

0% (0/9)

0% (0/8)

RP to scleroderma > 1 y

25% (4/16) 6

53% (10/19)

58% (7/12)

50% (4/8)

57% (4/7)

RP to scleroderma

(year, mean ± SD)

1.5 ± 5.37, 8

(0.2 ± 1.2)9

4.1 ± 8.9

5.7 ± 5.87

1.1 ± 1.7

2.6 ± 3.4

  1. RP, Raynaud's phenomenon
  2. 1 RNAP III vs others, P = 0.01; 2 RNAP III vs Topo I, P = 0.07; 3 RNAP III vs Topo I, P = 0.03; 4 RNAP III vs ACA, P = 0.04; 5 RNAP III vs others, P = 0.002; 6 RNAP III vs others, P = 0.08; 7 RNAP III vs ACA, P = 0.03; 8 RNAP III vs others, P = 0.03; 9 Value after excluding an outlier that has 21 years interval between RP to scleroderma.
  3. 1-6 by Fisher's exact test, 7,8 by Mann-Whitney